Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Brensocatib reduced bronchiectasis exacerbations

Publish date:: July 8, 2020

Key clinical point: Brensocatib may be an effective nonantibiotic agent for treating inflammation in bronchiectasis.

Major finding: Both the 10-mg and 25-mg doses of brensocatib reduced exacerbations, compared with placebo.

Study details: Randomized placebo-controlled trial comparing two brensocatib doses in 256 adults with bronchiectasis.

Disclosures: Dr. Chalmers disclosed consultancy with and research funding from Insmed, which funded the study. Dr. Taylor-Cousar has disclosed grants and/or personal fees from various companies.

Citation:

FROM ATS 2020

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

Osteoporosis prevalence in PsA similar to general population,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

DOACs look safe in elective endoscopic procedures,

Anorexia and diarrhea top list of GI symptoms in COVID-19 patients,

Must Reads in Pulmonology

E-cigarette use tied to increased COPD, asthma risk,

Obesity, hypoxia predict severity in children with COVID-19,

Telehealth finds acceptance among patients with CF, clinicians,

COVID-19 burdens follow patients after discharge,

Poverty raises depression risk in patients with cystic fibrosis,